Results 291 to 300 of about 2,453,090 (361)

Letter on “Real‐World Clinical Experience With Serum MOG and AQP4 Antibody Testing by Live Versus Fixed Cell‐Based Assay”

open access: yes
Annals of Clinical and Translational Neurology, EarlyView.
Raveena Vij   +2 more
wiley   +1 more source

Development of a personalized visualization and analysis tool to improve clinical care in complex multisystem diseases with application to scleroderma

open access: yesArthritis Care &Research, Accepted Article.
Background In complex diseases, it is challenging to assess a patient's disease state, trajectory, treatment exposures, and risk of multiple outcomes simultaneously, efficiently and at the point of care. Methods We developed an interactive patient‐level data visualization and analysis tool (VAT) that automates illustration of a scleroderma patient's ...
Ji Soo Kim   +18 more
wiley   +1 more source

Reply to Letter: “Real‐World Clinical Experience With Serum MOG and AQP4 Antibody Testing by Live Versus Fixed Cell‐Based Assay”

open access: yes
Annals of Clinical and Translational Neurology, EarlyView.
Yana Said   +2 more
wiley   +1 more source

Lived and care experiences of chronic musculoskeletal shoulder pain in Australian adults: A qualitative study

open access: yesArthritis Care &Research, Accepted Article.
Objectives Australian evidence on lived and care experiences of chronic musculoskeletal shoulder pain (CMSP), irrespective of disorder classification or disease, is limited. However, such evidence is important for person‐centred care and informing local service pathways and care guidelines or standards.
Sonia Ranelli   +8 more
wiley   +1 more source

Global and regional temporal changes in cross‐country inequalities of site‐specific osteoarthritis burden, 1990–2021

open access: yesArthritis Care &Research, Accepted Article.
Objective This study examined the global and regional temporal changes in cross‐country inequalities of site‐specific osteoarthritis (OA) burden from 1990 to 2021. Methods Age‐standardized years lived with disability rate for site‐specific OA across 204 countries/territories were obtained from the Global Burden of Diseases Study (GBD) 2021.
Haowei Chen   +14 more
wiley   +1 more source

Improvements in Health‐Related Quality of Life with Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post‐hoc Analysis of a Randomized Multicenter Trial

open access: yesArthritis Care &Research, Accepted Article.
Background While treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL change.
Austin Barry   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy